Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (AAVXF) Research & Development (2024 - 2025)

Historic Research & Development for Abivax (AAVXF) over the last 2 years, with Q3 2025 value amounting to -$64.8 million.

  • Abivax's Research & Development fell 3628.04% to -$64.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year change of. This contributed to the annual value of $156.6 million for FY2024, which is 4029.85% up from last year.
  • Abivax's Research & Development amounted to -$64.8 million in Q3 2025, which was down 3628.04% from -$43.7 million recorded in Q2 2025.
  • Abivax's Research & Development's 5-year high stood at $271.9 million during Q4 2024, with a 5-year trough of -$64.8 million in Q3 2025.